Carrying Alzheimer’s Drugs Into the Brain on Waves of Sound
In the last three years, amyloid plaque-busting drugs Aduhelm (now discontinued) and Leqembi have been approved by the FDA for treating patients in the…
In the last three years, amyloid plaque-busting drugs Aduhelm (now discontinued) and Leqembi have been approved by the FDA for treating patients in the…
As Alzheimer’s and other forms of dementia progress, brain cells and their connections degenerate and die, including those crucial for recalling old memories. That…
Even after decades of studying Alzheimer’s, Parkinson’s, and other similar conditions, scientists still don’t know what exactly causes the disease to develop. What they…
In 2013, 29-year-old Ben Stecher went to the doctor with concerning symptoms — he felt like he was moving in slow-motion, and his hands…
A brain stimulation technique called transcranial magnetic stimulation (TMS) is sparking the attention of neurologists around the globe. In the U.S., it’s already FDA…
Dementia is most widely associated with its cognitive symptoms, like memory loss. But it often brings a host of behavioral symptoms, too, like agitation…
Researchers in Tokyo continue encouraging research on oxytocin as a potential Alzheimer’s drug target. When administered nasally, the hormone appeared to reverse cognitive decline…
Canine cognitive dysfunction looks a lot like Alzheimer’s and dementia in humans. Could a disease-modifying intervention that seems effective our furry companions also work for…
The media is reporting that recent fraud allegations undermine the leading theory about the cause of Alzheimer’s. But some of the field’s most established…
Better Alzheimer’s treatments are going to require better models of Alzheimer’s brains in the lab, researchers say. Psychology researcher Étienne Aumont at the University…
University of Colorado associate professor of health economics Joan O’Connell and University of California Irvine associate professor of epidemiology Luohua Jiang share insights from…
A Phase 2a clinical trial is underway to test the possible benefits of sodium selenate for people living with frontotemporal dementia. While Alzheimer’s is…
UPDATE: 3 March 2024, 8:18 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
Apathy is an extremely common symptom of Alzheimer’s. It impairs patients’ ability to socialize and maintain routines, activities that are central to preserving their…
An emerging brain technology — transcranial magnetic stimulation — offers a non-invasive way to change the brain for the better, using magnets. Proponents believe…